Article
Predicting neoadjuvant treatment response in triple-negative breast cancer using machine learning
2023-04-20
Abstract excerpt
<h4>Background</h4> Neoadjuvant chemotherapy (NAC) is the standard treatment for early-stage triple negative breast cancer (TNBC). The primary endpoint of NAC is a pathological complete response (pCR). NAC results in pCR in only 30%–40% of TNBC patients. Tumor-infiltrating lymphocytes (TILs), Ki67 and phosphohistone H3 (pH3) are a few known biomarkers to predict NAC response. Currently, systematic evaluation of t...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- fecc1bf2-7d34-59cf-96cb-53ad5f8ccb2c
- DOI
- 10.1101/2023.04.17.536459
